Growth Opportunity Analysis in the Global Biologics Outsourcing Market

The global biologics outsourcing market is expected to grow at a CAGR of around 12.5% over the forecast period. The market growth is attributed to the increasing adoption of advanced technologies for biological production, a rise in outsourcing of R&D activities by pharmaceutical and biopharmaceutical companies and a favorable regulatory environment for clinical trials in developing countries. Further, the increase in the number of mergers and collaborations has increased pharmaceutical and biopharmaceutical outsourcing, with major industry players expanding into developing regions. For instance, in May 2019, Thermo Fisher Scientific, Inc. acquired Brammer Bio, a viral vector contract developer for gene and cell therapies, to strengthen its market position in the area of gene therapy.

Market Segmentation 
The global biologics outsourcing market has been analyzed on the basis of product type, source, application, end-use, and region. Based on the product type, the market is segmented into antibodies, recombinant proteins, vaccines, and others. Among these, antibodies segment is estimated to hold a prominent share in the market. Based on source, the market is segmented into human, microbial, and others. The microbial segment is projected to exhibit a considerable growth during the forecast period. 
Based on application, the market is segmented into stem cell research, vaccine and therapeutics development, blood & blood-related products development, cellular and gene therapy products development, and others. Stem cell research segment is estimated to hold a prominent share in the market. Based on end-user, the market covers the analysis of therapeutics & diagnostics, and research. Geographically, the market is analyzed into North America, Western Europe, Eastern Europe, Asia Pacific, Latin America, and Middle East & Africa.

Market Structure and Competition Landscape 
The global biologics outsourcing market is characterized by the presence of significant number of players. Some of the prominent players operating in the market include Lonza Group AG, Wuxi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Samsung Biologics Co. Ltd., Thermo Fisher Scientific Inc., Wuxi Biologics (Cayman) Inc., Genescript Biotech Corp., and others. Growing focus on biologics and increasing R&D spending on biologics drugs by these industry players are expected to drive the market. Some of the key developments in the global biologics outsourcing market include:
• In January 2022, Samsung Biologics agreed to pay US$ 2.3 billion for Biogen’s 50% stake in Samsung Bioepis, a joint venture between the two companies. This is aimed to improve Samsung Bioepis’ biosimilar development capabilities and future performance in new drug development.
• In March 2021, WuXi acquired a single-use biologics production plant in Hangzhou, China, from Pfizer Inc.